A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections
The purpose of the study is to compare the safety and efficacy of Isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.
Stanford is now accepting new patients for this trial.
- drug : Isavuconazole
- drug : Voriconazole
- drug : Caspofungin
Phase: Phase 3
Ages Eligible For Study:
- Patients with candidemia or with an invasive Candida infection - Presence of fever, hypothermia or other appropriate local sign of infection - Female patients must be non-lactating and at no risk of pregnancy